![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 49829](https://www.bertin-technologies.com/wp-content/uploads/2022/08/Group-56.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 49831](https://www.bertin-technologies.com/wp-content/uploads/2022/08/Group-57.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51209](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-cbrn-1.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 49833](https://www.bertin-technologies.com/wp-content/uploads/2022/08/Group-58.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 49835](https://www.bertin-technologies.com/wp-content/uploads/2022/08/Group-59.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51211](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-space-big-science-1.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51200](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-optronics.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51204](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-optomechanical.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51202](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-photonics.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51212](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-application-center.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51214](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-distributor-map.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51216](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-register-1.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51218](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-media.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 51220](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-faq.svg)
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 69984](https://www.bertin-technologies.com/wp-content/uploads/2024/06/about-us-2.png){kind=small}
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 69981](https://www.bertin-technologies.com/wp-content/uploads/2024/06/governance.png){kind=small}
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 69990](https://www.bertin-technologies.com/wp-content/uploads/2024/06/business-units.png){kind=small}
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 69987](https://www.bertin-technologies.com/wp-content/uploads/2024/06/subsidiaries.png){kind=small}
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 69997](https://www.bertin-technologies.com/wp-content/uploads/2024/06/location.png){kind=small}
![[PUBLICATION PRECELLYS] Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling Bertin Technologies 70000](https://www.bertin-technologies.com/wp-content/uploads/2024/06/certifications.png){kind=small}
Abstract
Background
Rapid, non-genomic estrogen receptor (ER) signaling plays an integral role in mediating the tissue selective properties of ER modulators. Icariin, a bone bioactive flavonoid, has been reported to selectively activate non-genomic ERα signaling in in vitro and in vivo studies.
Purpose
The mechanisms underlying the estrogen-like bone protective effects of icariin are not fully understood, especially those that are related to insulin-like growth factor I (IGF-1) signaling. The bone protective effects of icariin were investigated in female mature ovariectomized (OVX) rats and the signaling of IGF-IR- ERα cross-talk was determined in osteoblastic cells.
Sample type
Rat bone samples
Target
RNA Extraction
